Valneva CEO Interview - Stratégie du Groupe (video)

PARIS, January 29, 2019 /PRNewswire/ --

Valneva SE, société de biotechnologie dédiée au développement, à la production et à la commercialisation de vaccins innovants. Thomas Lingelbach, Président du directoire, commente la stratégie du Groupe

Visionner l'interview vidéo et lire la transcription : https://www.eurobusinessmedia.com/video/valneva-group-strategy?utm_source=ceo-direct&utm_medium=wire  

Au sommaire de l'interview 

- La Société - Les principales sources de revenus - Portefeuille de vaccins - Evolution de la société

About Valneva SE 

Valneva is a biotech company developing and commercializing vaccines for infectious diseases with major unmet needs. Valneva's portfolio includes two commercial vaccines for travelers: IXIARO(R)/JESPECT(R) indicated for the prevention of Japanese encephalitis and DUKORAL(R) indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has various vaccines in development including a unique vaccine against Lyme disease. Valneva has operations in Austria, Sweden, the United Kingdom, France, Canada and the US with approximately 500 employees. More information is available at http://www.valneva.com .